An in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin
The interaction of long circulating drugs with biological molecules might trigger harmful side effects. Here, the authors design an anticoagulant compound that can be deactivatedin vivo using click chemistry, paving the way to the design of drugs with tunable in vivoproperties.
Enregistré dans:
Auteurs principaux: | Sylvain Ursuegui, Marion Recher, Wojciech Krężel, Alain Wagner |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ebda2b9fe32443d9b94c7789c9666492 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
par: Ashley G. Woodhouse, et autres
Publié: (2019) -
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
par: Masanobu Ishii, et autres
Publié: (2017) -
Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
par: Clara Bonanad, et autres
Publié: (2021) -
Dorsal Spinal Chronic Subdural Hematoma Complicating Warfarin/Asprin Anticoagulation Therapy: A Case Report Study.
par: Emad Ghanem, et autres
Publié: (2012) -
Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
par: Dong Lin, et autres
Publié: (2021)